Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05187624
Recruitment Status : Recruiting
First Posted : January 12, 2022
Last Update Posted : August 3, 2022
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).

Condition or disease Intervention/treatment Phase
Glioblastoma Drug: RO7428731 Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III
Actual Study Start Date : April 5, 2022
Estimated Primary Completion Date : February 6, 2025
Estimated Study Completion Date : February 6, 2025

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Part I: Dose Escalation
Participants with newly diagnosed GBM will receive RO7428731, intravenously (IV), up to one year or until disease progression, withdrawal of consent, unacceptable toxicity, or death, whichever occurs first.
 Drug: RO7428731
Participants will receive RO7428731 as described.
Experimental: Part II: Dose-Expansion(s)
Participants with newly diagnosed GBM will receive RO7428731, IV, in maximum of two dose expansion cohorts at a dose(s) not exceeding the maximum tolerated dose (MTD) established in Part I.
 Drug: RO7428731
Participants will receive RO7428731 as described.
Experimental: Part III: Safety Run-in
Participants with recurrent GBM will receive RO7428731, IV in a dosing schedule determined in Part I. At the end of the Safety Run-in period, a decision will be made as to whether to open the Dose-Expansion Cohort Part IVA or open a second Safety Run-in Cohort at a lower dose.
 Drug: RO7428731
Participants will receive RO7428731 as described.
Experimental: Part IV A: Dose-Expansions Cohort
Participants with recurrent GBM will receive RO7428731, IV at specified doses and dosing schedules.
 Drug: RO7428731
Participants will receive RO7428731 as described.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of Participants with Adverse Events (AEs) [ Time Frame: Up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  2. Percentage of Participants with Dose Limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (each cycle is 21 days) ]

Secondary Outcome Measures :
  1. Maximum Plasma Concentration (Cmax) of RO7428731 [ Time Frame: Up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  2. Time to Maximum Plasma Concentration (Tmax) of RO7428731 [ Time Frame: Up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  3. Minimum Observed Serum Concentration (Cmin) of RO7428731 [ Time Frame: Up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  4. Clearance (CL) of RO7428731 [ Time Frame: Up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  5. Half-life (t1/2) of RO7428731 [ Time Frame: Up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  6. Volume of Distribution at Steady State (Vss) of RO7428731 [ Time Frame: Up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  7. Area Under the Plasma Concentration-Time Curve (AUC) of RO7428731 [ Time Frame: Up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  8. Percentage of Participants With RO7428731 Anti-drug Antibodies (ADAs) [ Time Frame: From baseline up to the safety follow-up visit 60 days after the last treatment (up to approximately 15 months) ]
  9. Objective Response Rate (ORR) [ Time Frame: From start of study treatment up to approximately 3 years ]
  10. Disease Control Rate (DCR) [ Time Frame: From start of study treatment up to approximately 3 years ]
  11. Duration of Response (DOR) [ Time Frame: From the time of first occurrence of a documented response until the time of documented disease progression or death (death within 30 days from last study treatment) from any cause, whichever occurs first (up to approximately 3 years) ]
  12. Progression-free Survival (PFS) [ Time Frame: From start of study treatment to the first occurrence of documented disease progression or death from any cause, whichever occurs first (up to approximately 3 years) ]
  13. Overall Survival (OS) [ Time Frame: From start of study treatment to the time of death from any cause (up to approximately 3 years) ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion criteria for all participants:

  • Life expectancy of greater than or equal to 12 weeks, in the opinion of the Investigator
  • Diagnosis of GBM based on the Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (cIMPACT) NOW 6 criteria
  • Participants must have confirmed EGFRvIII-expression
  • Karnofsky Performance Status (KPS) Score of >=70%.
  • Adequate organ functions prior to start of study treatment
  • Willingness to abide by contraceptive measures for the duration of the study.

Inclusion criteria for Part I and Part II only:

  • Participants whose tumors have an unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promotor status based on local assessment
  • Participants must have completed standard of care therapy for newly diagnosed disease, including surgical resection and adjuvant radiotherapy with or without concomitant temozolomide.

Inclusion criteria for Part III and Part IV only:

  • Documented first or second recurrence of GBM
  • At least one measurable GBM lesion as per RANO criteria prior to initiation of study treatment.

Exclusion Criteria:

Exclusion criteria for all participants:

  • Participants with infratentorial tumors and tumors primarily located in or close to critical structures (e.g., brain stem).
  • Presence of extracranial metastatic or leptomeningeal disease
  • Known hypersensitivity to immunoglobulins or to any other component of the investigational medicinal product formulation
  • Active bleeding or pathological condition that carries a high risk of bleeding, including inherited and acquired coagulopathies
  • Participants unable to undergo an MRI with contrast.

Exclusion criteria for Part I and Part II only:

  • Recurrent malignant gliomas
  • Any prior anti-tumor treatment for GBM: tumor resection, adjuvant radiotherapy with or without concomitant temozolomide must be the only tumor-directed treatment that the participant has received for GBM.

Exclusion criteria for Part III and Part IV only:

  • More than two recurrences of GBM
  • Prior anti-EGFRvIII-targeting agents (including vaccines), anti-angiogenic therapy, and/ or gene therapy for the treatment of GBM and gliomas.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05187624


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: BP42573 https://forpatients.roche.com/ 888-662-6728 (U.S. Only) global-roche-genentech-trials@gene.com

Locations
Layout table for location information
Australia, Victoria
Peter MacCallum Cancer Centre; Medical Oncology Recruiting
Melbourne, Victoria, Australia, 3000
Canada, Ontario
Princess Margaret Cancer Center Recruiting
Toronto, Ontario, Canada, M5G 1Z5
Denmark
Rigshospitalet, Onkologisk Klinik; Klinisk Forskningsenhed Recruiting
København Ø, Denmark, 2100
Spain
Clinica Universitaria de Navarra Recruiting
Pamplona, Navarra, Spain, 31008
Vall d´Hebron Institute of Oncology (VHIO), Barcelona Active, not recruiting
Barcelona, Spain, 08035
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT05187624    
Other Study ID Numbers: BP42573
2021-001197-37 ( EudraCT Number )
First Posted: January 12, 2022    Key Record Dates
Last Update Posted: August 3, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
 Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue